• 1.

    Caza T, et al.. NELL1 is a target antigen in malignancy-associated membranous nephropathy. Kidney Int [published online ahead of print August 20, 2020]. doi: 10.1016/j.kint.2020.07.039

    • Search Google Scholar
    • Export Citation
  • 2.

    Sethi S, et al.. Exostosin 1/exostosin 2-associated membranous nephropathy. J Am Soc Nephrol 2019; 30:11231136. doi: 10.1681/ASN.2018080852

  • 3.

    Fervenza FC, et al.. MENTOR Investigators. Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med 2019; 381:3646. doi: 10.1056/NEJMoa1814427

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Fernández-Juárez G, et al.. STARMEN Investigators. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Kidney Int [published online ahead of print November 7, 2020]. doi: 10.1016/j.kint.2020.10.014

    • Search Google Scholar
    • Export Citation
  • 5.

    Delbarba E, et al.. Rituximab vs. cyclosphosphamide in the treatment of membranous nephropathy: The RI-CYCLO trial. Presented as Poster PO2638 at Kidney Week Reimagined virtual conference, October 19–25, 2020.

    • Search Google Scholar
    • Export Citation
  • 6.

    Furie R, et al.. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med 2020; 383:11171128. doi: 10.1056/NEJMoa2001180

  • 7.

    Dooley MA, et al.. ALMS Group. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011; 365:18861895. doi: 10.1056/NEJMoa1014460

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Rovin BH, et al.. Management of lupus nephritis (LN) with voclosporin: An update from a pooled analysis of 534 patients. Presented as Poster PO1917 at Kidney Week Reimagined virtual conference, October 19–25, 2020.

    • Search Google Scholar
    • Export Citation
  • 9.

    Rauen T, et al.. STOP-IgAN Investigators. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 2015; 373:22252236. doi: 10.1056/NEJMoa1415463

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Lv J, et al.. TESTING Study Group. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: The TESTING randomized clinical trial. JAMA 2017; 318:432442. doi: 10.1001/jama.2017.9362

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11.

    Heerspink HJL, et al.. DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383:14361446. doi: 10.1056/NEJMoa2024816

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12.

    Walsh M, et al.. PEXIVAS Investigators. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med 2020; 382:622631. doi: 10.1056/NEJMoa1803537

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13.

    Merkel PA, et al.. OP0011 A randomized, double-blind, active-controlled study of avacopan in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Ann Rheum Dis 2020; 79:8. doi: 10.1136/annrheumdis-2020-eular.1073

    • Crossref
    • Search Google Scholar
    • Export Citation

2021: Year of the Glomerulus

  • 1 Kenar D. Jhaveri, MD, is a professor of medicine at Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and an attending nephrologist at Northwell Health, Long Island, NY, and is editor-in-chief of ASN Kidney News.
Restricted access
Save